

Brilliant Violet 510™ anti-human CD134 (OX40)

Catalog # / Size: 2350130 / 100 tests
2350125 / 25 tests

Clone: Ber-ACT35 (ACT35)

Isotype: Mouse IgG1, κ


Immunogen: HTLV 1-transformed HUT 102 cells

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 510™ and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Concentration: Lot-specific




PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with CD3 FITC and CD134 (OX-40) (clone Ber-ACT35) Brilliant Violet 510™ (top), or mouse IgG1, κ Brilliant Violet 510™ isotype control (bottom).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research

purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes: Additional reported applications (for the relevant formats) include: Western blotting¹, immunoprecipitation¹, immunohistochemical staining^{2,3} of paraffin embedded⁷ and frozen tissue sections, ELISA⁴, and functional assay⁵. The LEAF™ or Ultra-LEAF™ purified antibody is recommended for functional assays (contact our [custom solutions team](#)).

Application References:

1. Latza U, *et al.* 1994. *Eur. J. Immunol.* 24:677. (WB, IP)
2. Durkop H, *et al.* 1995. *Brit. J. Haematol.* 91:927. (IHC)
3. Durkop H, *et al.* 1997. *Brit. J. Haematol.* 98:863. (IHC)
4. Willett B, *et al.* 2007. *J. Virol.* 81:9665. (ELISA)
5. Li M and Zhang Y. *et al.* 2005. *Cell. Mol. Immunol.* 2:467. (FA)
6. Gloviczki ML, *et al.* 2012. *Clin. J. Am. Soc. Nephrol.* 8:546. [PubMed](#)
7. Domingos PL, *et al.* 2012. *An. Bras. Dermatol.* 87:851. (IHC)

Description: CD134, also known as OX40 and TNFRSF4, is a 50 kD type I transmembrane glycoprotein. It is a member of the TNF receptor family. OX40 is expressed on activated T lymphocytes including Th1, Th2, Th17, and Treg cells. The interaction of OX40 with OX40L results in B cell proliferation and antibody secretion, regulation of primary T cell expansion, and T cell survival. OX40 influences the size of the T cell memory pool and regulation of CD4⁺ T cell tolerance.

Antigen References:

1. Smith CA, *et al.* 1994. *Cell.* 76:959.
2. Chen AL, *et al.* 1999. *Immunity.* 11:689.
3. Croft M. 2010. *Annu. Rev. Immunol.* 28:57.
4. Ruby CE, *et al.* 2009. *J. Immunol.* 183:5079